Arrowhead Pharmaceuticals, Inc. (ARWR) EPS Estimated At $-0.15

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

Analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report $-0.15 EPS on December, 11.They anticipate $0.01 EPS change or 7.14 % from last quarter’s $-0.14 EPS. After having $-0.18 EPS previously, Arrowhead Pharmaceuticals, Inc.’s analysts see -16.67 % EPS growth. The stock decreased 0.62% or $0.09 during the last trading session, reaching $14.52. About 1.08M shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 456.10% since December 2, 2017 and is uptrending. It has outperformed by 440.48% the S&P500.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 3 analysts covering Arrowhead Research (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arrowhead Research had 4 analyst reports since June 18, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of ARWR in report on Monday, June 18 with “Buy” rating. As per Thursday, September 6, the company rating was upgraded by FBR Capital. The firm earned “Neutral” rating on Wednesday, August 8 by FBR Capital. The firm has “Buy” rating by Chardan Capital Markets given on Thursday, September 6.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company has market cap of $1.28 billion. The Company’s pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. It currently has negative earnings. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.

More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Nasdaq.com which released: “Arrowhead Pharmaceuticals Inc. (ARWR) Has Risen To A New High On Study Data – Nasdaq” on September 06, 2018, also Nasdaq.com with their article: “Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today – Nasdaq” published on June 18, 2018, Benzinga.com published: “Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results, IPOs (Nov. 11-17) – Benzinga” on November 11, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: Seekingalpha.com and their article: “Arrowhead Surges Forward With Major Deal And Its Intentions Were Highly Misunderstood – Seeking Alpha” published on October 08, 2018 as well as Seekingalpha.com‘s news article titled: “Arrowhead Pharmaceuticals – Pullbacks Are Becoming Rare, So Take Advantage If You Love The Potential – Seeking Alpha” with publication date: June 22, 2018.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.